Microbiome-derived inosine modulates response to checkpoint inhibitor immunotherapy
The DOI matches its Crossref record; 65 of the 65 references it cites were found in a registry or an index.
Abstract
Inosine modulates antitumor immunity: Checkpoint blockade immunotherapy harnesses the immune system to kill cancer cells and has been used with great success to treat certain tumors, but not all cancer patients respond. The efficacy of checkpoint blockade immunotherapy has been shown to depend on the presence of distinct, beneficial bacteria residing in the gut of patients, but how the microbiome mediates such beneficial effects is unclear. Mager et al. found that specific bacteria produce a metabolite called inosine that enhances the effect of checkpoint blockade immunotherapy (see the Perspective by Shaikh and Sears). In mouse models, inosine, together with proinflammatory stimuli and immunotherapy, strongly enhanced the antitumor capacities of T cells in multiple tumor types, including colorectal cancer, bladder cancer, and melanoma. Science , this issue p. 1481 ; see also p. 1427
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Inosine, the purine metabolite of Akkermansia muciniphila and Bifidobacterium pseudolongum (B. pseudolongum), plays a vital role in improving the efficacy of ICI [51].”
From Gut microbiota influence immunotherapy responses: mechanisms and therapeutic strategies (2022) · doi:10.1186/s13045-022-01273-9 · cites this paper as [51]
In the citing paper
“The inosine-A2AR-cAMP-PKA signaling cascade led to the phosphorylation of cAMP response element-binding protein (pCREB), which upregulated IL12Rβ2 and IFNγ transcription and promoted Th1-cell differentiation and accumulation in the TME [51].”
From Gut microbiota influence immunotherapy responses: mechanisms and therapeutic strategies (2022) · doi:10.1186/s13045-022-01273-9 · cites this paper as [51]
In the citing paper
“The gut microbial metabolite inosine could improve the efficacy of ICI by acting on adenosine 2A receptor (A2AR) on T lymphocytes in intestinal cancer, bladder cancer, and melanoma mouse models [51].”
From Gut microbiota influence immunotherapy responses: mechanisms and therapeutic strategies (2022) · doi:10.1186/s13045-022-01273-9 · cites this paper as [51]
In the citing paper
“Moreover, specific gut microbes, such as Bifidobacterium [16, 33, 51, 141], Akkermansia [31, 38], Enterococcus [15, 33, 141], Faecalibacterium [49, 142], and Ruminococcaceae [32], play the role of immune adjuvants in ICI immunotherapy.”
From Gut microbiota influence immunotherapy responses: mechanisms and therapeutic strategies (2022) · doi:10.1186/s13045-022-01273-9 · cites this paper as [51]
In the citing paper
“for example, anti-CTLA-4 appears to modify gut barrier integrity 51 and thus could feasibly change microbial compositions”
From A gut microbial signature for combination immune checkpoint blockade across cancer types (2024) · cites this paper as [51]
7 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2
Love, M. I., Huber, W., & Anders, S. (2014) · Genome Biology · doi:10.1186/s13059-014-0550-8 · Cited by 95,106
DADA2: High–resolution sample inference from Illumina amplicon data
Callahan, B. J., McMurdie, P. J., Rosen, M. J., Han, A. W., Johnson, A. J. A., & Holmes, S. P. (2016) · Nature Methods · doi:10.1038/nmeth.3869 · Cited by 35,698
Improved Survival with Ipilimumab in Patients with Metastatic Melanoma
Hodi, F. S., O'Day, S. J., McDermott, D. F., Weber, R. W., Sosman, J. A., Haanen, J. B., Gonzalez, R., Robert, C., Schadendorf, D., Hassel, J. C., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1003466 · Cited by 15,155
16S ribosomal DNA amplification for phylogenetic study
Weisburg, W. G., Barns, S. M., Pelletier, D. A., & Lane, D. J. (1991) · Journal of Bacteriology · doi:10.1128/jb.173.2.697-703.1991 · Cited by 11,934
Greengenes, a Chimera-Checked 16S rRNA Gene Database and Workbench Compatible with ARB
DeSantis, T. Z., Hugenholtz, P., Larsen, N., Rojas, M., Brodie, E. L., Keller, K., Huber, T., Dalevi, D., Hu, P., & Andersen, G. L. (2006) · Applied and Environmental Microbiology · doi:10.1128/aem.03006-05 · Cited by 10,891
PD-1 Blockade in Tumors with Mismatch-Repair Deficiency
Le, D. T., Uram, J. N., Wang, H., Bartlett, B. R., Kemberling, H., Eyring, A. D., Skora, A. D., Luber, B. S., Azad, N. S., Laheru, D., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1500596 · Cited by 9,377
Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer
Borghaei, H., Paz-Ares, L., Horn, L., Spigel, D. R., Steins, M., Ready, N. E., Chow, L. Q., Vokes, E. E., Felip, E., Holgado, E., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1507643 · Cited by 9,335
Safety and activity of anti-PD-L1 antibody in patients with advanced cancer
Brahmer, J. R., Tykodi, S. S., Chow, L. Q. M., Hwu, W.-J., Topalian, S. L., Hwu, P., Drake, C. G., Camacho, L. H., Kauh, J., Odunsi, K., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1200694 · Cited by 7,945
Kozich, J. J., Westcott, S. L., Baxter, N. T., Highlander, S. K., & Schloss, P. D. (2013) · Applied and Environmental Microbiology · doi:10.1128/aem.01043-13 · Cited by 7,112
Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade
Le, D. T., Durham, J. N., Smith, K. N., Wang, H., Bartlett, B. R., Aulakh, L. K., Lu, S., Kemberling, H., Wilt, C., Luber, B. S., et al. (2017) · Science · doi:10.1126/science.aan6733 · Cited by 6,645
Cited by
Items 701–800 of 1,004
Yang, F., Zhou, L., Shen, Y., Zhao, S., Zheng, Y., Men, R., Fan, X., & Yang, L. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.982186 · Cited by 12
“Increasing evidence demonstrates that inosine possesses a wide range of anti-inflammatory and immunomodulatory properties (14, 23).”
BackgroundDrommi, F., Calabrò, A., Vento, G., Pezzino, G., Cavaliere, R., Omero, F., Muscolino, P., Granata, B., D’Anna, F., Silvestris, N., et al. (2023) · Cancers · doi:10.3390/cancers15112893 · Cited by 14
“In this regard, it has been reported that a decrease in either the number or activity of ILC3s results in marked reductions in commensal Bacteroides and Lactobacilli [40], strains that are positively associated with ICI responsiveness in CRC [75].”
BackgroundPotential role of intratumor bacteria outside the gastrointestinal tract: More than passengers
Liu, Z., Hong, L., & Ling, Z. (2023) · Cancer Medicine · doi:10.1002/cam4.6298 · Cited by 13
The emerging role of the gut microbiome in cancer cell plasticity and therapeutic resistance
Mondal, P., & Meeran, S. M. (2023) · Cancer and Metastasis Reviews · doi:10.1007/s10555-023-10138-7 · Cited by 12
Menard, J. M., Bagheri, S., Menon, S., Yu, Y. T., & Goodman, L. B. (2023) · Animal Microbiome · doi:10.1186/s42523-023-00286-0 · Cited by 12
“The metabolite extraction was performed using a methanol and acetonitrile-based protocol adopted from previously published studies [44–46] for the isolation of polar metabolites for downstream untargeted HILIC Liquid Chromatography–Mass Spectrometry analysis.”
MethodAl-Khazaleh, A. K., Chang, D., Münch, G., & Bhuyan, D. (2024) · Cancers · doi:10.3390/cancers16081464 · Cited by 8
“Although the precise mechanisms of action for each bacteriocin remain elusive, their ability to bind to lipid II, the primary transporter of peptidoglycans from the cytoplasm to the cell wall, has been identified as an effective mechanism in various studies [69].”
BackgroundMicrobiome engineering: unlocking therapeutic potential in inflammatory bowel disease
Chen, K., Huang, L.-B., Yang, M., Yue, N.-N., Luo, D., Zhang, Y., Tian, C., Song, Y., Wei, D., Shi, R., et al. (2025) · Frontiers in Microbiology · doi:10.3389/fmicb.2025.1610029 · Cited by 16
Intratumoral microbiome: the double-edged sword in remodeling cancer immunotherapy
Yan, D., Yu, Y., Liang, C., Cui, Z., Shi, L., Li, G., & Ren, C. (2026) · Molecular Cancer · doi:10.1186/s12943-025-02566-6 · Cited by 12
“Mechanistically, metabolites such as short-chain fatty acids (SCFAs) and inosine can enhance the activity and proliferation of CD8 + T cells [203, 204].”
Du, P., Jing, J., & He, X. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.1091124 · Cited by 15
“Another study demonstrated that inosine improved anti-tumor responses of immunotherapy in mouse models of various cancer types (Mager et al., 2020).”
BackgroundPrinciples and Terminology for Host–Microbiome–Drug Interactions
Heirali, A., Moossavi, S., Arrieta, M., & Coburn, B. A. (2023) · Open Forum Infectious Diseases · doi:10.1093/ofid/ofad195 · Cited by 13
Improving gut functions and egg nutrition with stevia residue in laying hens
Tang, M., Zhao, J., Wu, Y., Yu, C., Peng, C., Liu, H., Cui, Y., Lan, W., Lin, Y., Kong, X., et al. (2023) · Poultry Science · doi:10.1016/j.psj.2023.103324 · Cited by 11
“In terms of gut microbiota, STER increased the relative abundance of Actinobacteriota while inhibiting the relative abundance of Proteobacteria, Desulfobacterota , and Synergistota .”
BackgroundInfluentialThe role of intestinal flora on tumor immunotherapy: recent progress and treatment implications
Zhou, Y., Liu, X., Gao, W., Luo, X., Lv, J., Wang, Y., & Liu, D. (2023) · Heliyon · doi:10.1016/j.heliyon.2023.e23919 · Cited by 13
“Differences in individual intestinal flora are also associated with the development of irAEs; however, the underlying mechanism is unclear [174,175].”
BackgroundUnlocking CAR T cell potential: Inosine-induced stemness and enhanced potency
Zhang, X., & Wang, H. (2024) · Cancer Cell · doi:10.1016/j.ccell.2024.01.003 · Cited by 11
Yang, M., Shen, H., Zhong, S., Xu, Z., Liu, X., Wu, W., Mao, C., & Yang, M. (2024) · Aggregate · doi:10.1002/agt2.515 · Cited by 11
Gut bacteria, host immunity, and colorectal cancer: From pathogenesis to therapy
Li, Y., Peng, J., & Meng, X. (2024) · European Journal of Immunology · doi:10.1002/eji.202451022 · Cited by 11
Yin, Q., Ni, J., & Ying, J. (2024) · Immunity Inflammation and Disease · doi:10.1002/iid3.1263 · Cited by 13
“87 Another study also demonstrated that inosine offers an alternative carbon source for CD8 + T ‐ cell function in a glucose ‐ limited environment to support effective T ‐ cell growth and function as well as enhance the efficacy of ICIs.”
BackgroundNandi, D., & Sharma, D. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1477980 · Cited by 12
Gebeyew, K., Mi, H., Du, R., Gao, M., Diba, D., Tang, S., He, Z., & Tan, Z. (2024) · Animal nutrition · doi:10.1016/j.aninu.2024.08.010 · Cited by 11
Cuisiniere, T., Hajjar, R., Oliero, M., Calvé, A., Fragoso, G., Rendos, H. V., Gerkins, C., Taleb, N., Gagnon-Konamna, M., Dagbert, F., et al. (2025) · Microbiome · doi:10.1186/s40168-025-02101-1 · Cited by 12
“Consistent with this, a recent study revealed that B. pseudolongum and its derived inosine have anti-tumorigenic effects [71] linked to the enhancement of antitumor T cells function [72].”
Extracellular vesicles of Gram-negative and Gram-positive probiotics
Wang, Y., Duan, C., & Yu, X. (2025) · The Journal of Microbiology · doi:10.71150/jm.2506005 · Cited by 15
“This raises the potential for integrating microbiological therapies with immunotherapies to improve cancer treatment outcomes (Mager et al., 2020).”
Complex Role of Microbiome in Pancreatic Tumorigenesis: Potential Therapeutic Implications
Amara, S., Yang, L. V., Tiriveedhi, V., & Muzaffar, M. (2022) · Cells · doi:10.3390/cells11121900 · Cited by 12
“The bacterial species, Bifidobacterium pseudolongum, Lactobacillus johnsonii and Olsenella species have demonstrated enhanced efficacy of ICIs in four different murine cancer models through the production of inosine, which through interaction with adenosine A2A receptor induced anti-tumor CD4+T cell activation [96].”
BackgroundZou, W., Deng, L., Wu, H., Liu, Z., Lu, W., & He, Y. (2022) · Animals · doi:10.3390/ani12202879 · Cited by 11
“Pro-inflammatory substances can also cause diarrhea by impairing the intestinal mucosal barrier with pro-inflammatory cytokines [42], but quercetin [31], arteannuin and kynurenine [43,44], ferulic acid [45], purines [46], inosine [47,48], guanosine [49] and benzene-1,2,4-triol [50] can reduce diarrhea by increasing IF…”
BackgroundCrosstalk between Metabolite Production and Signaling Activity in Breast Cancer
Çubuk, C., Loucera, C., Peña-Chilet, M., & Dopazo, J. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24087450 · Cited by 12
Xia, Y., Hong, L., Zheng, J., Lu, Z., Zhang, Q., Chen, S., Pang, Z., Li, L., Qiao, S., Wang, Q., et al. (2023) · Journal of Materials Chemistry B · doi:10.1039/d3tb00714f · Cited by 11
Insights into vitamin A in bladder cancer, lack of attention to gut microbiota?
Luo, P., Zheng, L., Zou, J., Chen, T., Zou, J., Li, W., Chen, Q., & Qian, B. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1252616 · Cited by 15
“In addition, the influence of dietary intervention on the intestinal microbial composition of mice on bladder cancer has been assessed in several in vivo experiments (28, 127, 128).”
The Role of Tumor and Host Microbiome on Immunotherapy Response in Urologic Cancers
Drobner, J. C., Doppalapudi, K., Saraiya, B., Packiam, V. T., & Ghodoussipour, S. B. (2024) · Journal of Cancer Immunology · doi:10.33696/cancerimmunol.6.078 · Cited by 15
“These bacteria enhanced immunotherapy response by producing the metabolite inosine, which activated antitumor T-cells [67].”
BackgroundImpact of the microbiome on tumor immunity
McCoy, K. D., & Mager, L. F. (2021) · Current Opinion in Immunology · doi:10.1016/j.coi.2021.01.002 · Cited by 11
Self-citationBi-direction effects between microbiome and MiRNAs in carcinogenesis
Wang, Q., Ding, H., Dong, G., Xu, L., Jiang, F., & Mao, Q. (2021) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-021-03567-w · Cited by 11
Archetypes of checkpoint-responsive immunity
Im, K. W., Combes, A. J., Spitzer, M. H., Satpathy, A. T., & Krummel, M. F. (2021) · Trends in Immunology · doi:10.1016/j.it.2021.09.007 · Cited by 15
Uribe‐Herranz, M., Oliver‐Caldés, A., Martínez-Micaelo, N., Español‐Rego, M., Val-Casals, M., Martínez-Soler, R., Rubio-García, E., Brunello, V., Mihelic, E. Z., Klein-González, N., et al. (2025) · Blood Cancer Discovery · doi:10.1158/2643-3230.bcd-24-0203 · Cited by 12
Leung, E. L., Huang, J., Zhang, J., Zhang, J., Wang, M., Zhu, Y., Meng, Z., Yu, H., Neher, E., Ma, L., et al. (2023) · Antioxidants and Redox Signaling · doi:10.1089/ars.2021.0243 · Cited by 14
“Multiple studies have suggested that microbial metabolites potentiated the efficacy of immune checkpoint inhibitors (ICIs) (He et al, 2021; Luu et al, 2021; Mager et al, 2020).”
InfluentialFang, H., Li, H., Chen, Y., Liu, X., Zhao, J., Ross, R. P., Stanton, C., Chen, W., & Yang, B. K. (2024) · Food Bioscience · doi:10.1016/j.fbio.2024.104058 · Cited by 10
Majumder, B., Nataraj, N. B., Maitreyi, L., & Datta, S. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1414376 · Cited by 11
“Among different metabolites, bacteria-derived inosine acts via A2A adenosine receptor (A2AR) in Th1 cells, facilitates T cell and DC crosstalk and increases the metabolic fi tness of CD8+T cells to trigger tumor killing (98).”
BackgroundMicrobial molecules, metabolites, and malignancy
Thomas, R. M. (2025) · Neoplasia · doi:10.1016/j.neo.2025.101128 · Cited by 11
“However, Mager and colleagues recently reported that microbiome-derived inosine is responsible for ICI therapy responsiveness [89].”
The Skin Microbiome: A New Key Player in Melanoma, From Onset to Metastatic Stage
L'Orphelin, J. ‐., Dompmartin, A., & Dréno, B. (2025) · Pigment Cell & Melanoma Research · doi:10.1111/pcmr.13224 · Cited by 14
“Some pathogens can release metabolites that directly activate T lymphocytes, affect intestinal epithelial or endothelial barriers, or target tumor cells (Wang et al. 2020; Mager et al. 2020; Zhang et al. 2022).”
Expanding horizons of cancer immunotherapy: hopes and hurdles
Sonar, P. V., Singh, A. K., Mandadi, S., & Sharma, N. K. (2025) · Frontiers in Oncology · doi:10.3389/fonc.2025.1511560 · Cited by 12
Gut microbiome and colorectal cancer: From pathogenesis to treatment
Lahouty, M., Fadaee, M., Aghaei, R., Alizadeh, F., Jafari, A., & Sharifi, Y. (2025) · Pathology - Research and Practice · doi:10.1016/j.prp.2025.156034 · Cited by 11
Host-microbiota interactions in genitourinary cancer immunotherapy
Xu, X., Cui, J., Li, W., Xu, Y., Yuan, S., Zeng, X., & Li, B. (2025) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2025.07.005 · Cited by 12
Pamungkas, K. M. N., Dewi, P. I. S. L., Alamsyah, A. Z., Dewi, N. L. P. Y., Dewi, N. N. G. K., Mariadi, I. K., & Sindhughosa, D. A. (2025) · World Journal of Hepatology · doi:10.4254/wjh.v17.i7.106810 · Cited by 11
Wang, X., Ma, L., Chen, C., Ma, L., Qu, X., Ren, A., Zhou, Y., & Cheng, H. (2025) · Carbohydrate Polymers · doi:10.1016/j.carbpol.2025.124554 · Cited by 13
Microbial metabolites for cancer immunotherapy: Current evidence and future directions
Wang, X., Liang, J.-J., Duan, X., & Chen, G. (2025) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2025.10.005 · Cited by 12
Microbe-driven immune suppression in colorectal cancer: the Fusobacterium nucleatum playbook
Wuyi, W., & Tao, P. (2026) · Frontiers in Immunology · doi:10.3389/fimmu.2026.1795703 · Cited by 14
Khalyfa, A., Qiao, Z., Raju, M., Shyu, C., Coghill, L. M., Ericsson, A. C., & Gozal, D. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms221910616 · Cited by 11
Liu, Y., Xue, Y., Zhang, Z., Ji, J., Li, C., Zheng, K., Lu, J., Gao, Y., Gong, Y., Zhang, Y., et al. (2022) · The FASEB Journal · doi:10.1096/fj.202200945r · Cited by 14
NLRP6 deficiency expands a novel CD103+ B cell population that confers immune tolerance in NOD mice
Pearson, J. A., Peng, J., Huang, J., Yu, X.-Q., Tai, N., Hu, Y., Sha, S., Flavell, R. A., Zhao, H., Wong, F. S., et al. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1147925 · Cited by 11
“Inosine, one of the upstream regulators of NLRP6-deficient CD103 Bregs, can also be produced by the microbiota and is important in inhibition of severe autoimmunity (50), and improving the efficacy of checkpoint inhibitor therapy in colorectal cancer (51).”
BackgroundWang, M., Huang, Y., Xin, M., Li, T., Wang, X., Fang, Y., Liang, S., Cai, T., Xu, X., Dong, L., et al. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1156471 · Cited by 13
“pseudolongum has the ability to increase its response to immunotherapy by producing the metabolite inosine (126).”
BackgroundPersonalizing Oncolytic Immunovirotherapy Approaches
Stergiopoulos, G. M., Iankov, I. D., & Galanis, E. (2023) · Molecular Diagnosis & Therapy · doi:10.1007/s40291-023-00689-4 · Cited by 10
“In addition, recent reports on the systemic translocation of inosine produced by Bifidobacterium as an activator of T cells and antitumor immunity [180] highlighted that microbiota metabolomics should be incorporated into personalized therapeutic algorithms.”
Kong, Y., Liu, S., Wang, X., & Qie, R. (2024) · Medicine · doi:10.1097/md.0000000000037628 · Cited by 11
“[44] This result was similarly confirmed in bladder cancer, kidney cancer, and melanoma.”
Yan, J., Wang, Z., Bao, G., Xue, C., Zheng, W., Fu, R., Zhang, M., Ding, J., Yang, F., & Sun, B. (2024) · Cell & Bioscience · doi:10.1186/s13578-024-01232-6 · Cited by 14
Bhutani, B., Sharma, V., Ganguly, N. K., & Rana, R. (2025) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2025.117987 · Cited by 10
Cable, J., Leonard, J. N., Lu, T. K., Xie, Z., Chang, M. W., Fernández, L. Á., Lora, J. M., Kaufman, H. L., Quintana, F. J., Geiger, R., et al. (2021) · Annals of the New York Academy of Sciences · doi:10.1111/nyas.14710 · Cited by 10
Zarour, H. M. (2022) · Cell Metabolism · doi:10.1016/j.cmet.2022.11.010 · Cited by 10
Gao, X., & Jiang, J. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1359029 · Cited by 12
“When administered in combination with anti-PD-1, LGG expedites interferon (IFN) production in DCs, enhancing the generation of anti-tumor CD8 + T cells.”
BackgroundInfluentialAn, X., Sun, S., Sun, J., Liao, R., Ma, R., Zhao, H., & Liu, Q. (2024) · Food Bioscience · doi:10.1016/j.fbio.2024.104643 · Cited by 10
Rodriguez-Marino, N. C., Royer, C. J., Rivera-Rodriguez, D. E., Seto, E., Gracien, I., Jones, R. M., Scharer, C. D., Gracz, A. D., & Cervantes‐Barragán, L. (2024) · Mucosal Immunology · doi:10.1016/j.mucimm.2024.08.010 · Cited by 9
Inosine Prevents Colorectal Cancer Progression by Inducing M1 Phenotypic Polarization of Macrophages
Ma, Y., Qian, X., Yu, Q., Dong, Y., Wang, J.-P., Liu, H., & Xiao, H. (2024) · Molecules · doi:10.3390/molecules30010123 · Cited by 10
“Clinically, it has been used to treat conditions like chronic hepatitis and Tourette’s syndrome in children [25].”
Immunosuppressant imprecision: multidirectional effects on metabolism and microbiome
Kensiski, A., Gavzy, S. J., Wu, L., Mas, V. R., Ma, B., & Bromberg, J. S. (2025) · Clinical Microbiology Reviews · doi:10.1128/cmr.00178-24 · Cited by 11
“In a murine model, inosine upregulates il12rb2, Tbx21, and ifng via the GPCR adenosine A 2A receptor on T cells, in turn promoting their activation to a Th1 state (152).”
The interactions between gut microbiota and Chinese herbal medicine in colorectal cancer
Hou, X., Li, X., Chen, W., Zhu, W., Guo, H., & Zhao, L. (2025) · Acupuncture and Herbal Medicine · doi:10.1097/hm9.0000000000000153 · Cited by 12
Narikawa, Y., Kuramasu, A., Hosonuma, M., Murayama, M., Funayama, E., Sasaki, A., Baba, Y., Toyoda, H., Isobe, J., Tajima, K., et al. (2025) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-025-04111-2 · Cited by 11
“Given that Bifidobacterium pseudolongum , a known inosine-producing species, is associated with improved responses to ICIs [14], both microbial composition and fecal inosine levels may serve as useful biomarkers to guide treatment strategies.”
InfluentialXian, Y., Chen, Z., Lan, Z., Zhang, C., Sun, H., Liu, Z., Kong, P., Liang, Y., Zhao, Y., Liu, S. M., et al. (2025) · Gut Microbes · doi:10.1080/19490976.2025.2557978 · Cited by 12
“37,38 Further investigation into the molecular mechanisms revealed that the regulation of MNC-168 may not solely rely on NOD2 signaling.”
Modulating Prostate Cancer Therapy Through the Gut Microbiome: A Comprehensive Review
Ali, M. A. M., & Abdulkadir, S. A. (2025) · Cancers · doi:10.3390/cancers17233842 · Cited by 9
“…Bifidobacterium pseudolongum , has been reported to improve ICI efficacy by enhancing tumor antigen presentation via IFN γ and TNF α pathways, activating T cells through adenosine A2A receptor signaling, and serving as an alternative carbon source for CD8+ T cells under metabolic stress [58–60].”
Tingting, Y., Xiaoling, Z., Zhang, Y., Luo, Y., Luo, Y., Xueqin, S., & Shikai, T. (2025) · Frontiers in Oncology · doi:10.3389/fonc.2025.1609889 · Cited by 10
“This interaction leads to the release of granzymes and perforin, which directly kill tumor cells and enhance the cytotoxic ef fi ciency of NK cells against tumor cells (28, 65).”
Lim, K. H. J., Schulz, O., Lobón, I., Castro‐Dopico, T., Zapata, L., Giampazolias, E., Frederico, B., Castellanos, C. A., Buck, M. D., Stainier, W., et al. (2026) · Nature Immunology · doi:10.1038/s41590-025-02354-w · Cited by 12
“The colitis-associated carcinoma model was established based on the protocol adapted from Mager et al. 57 , which involved 2 doses of AOM (Sigma-Aldrich, A5486) 10 mg kg −1 administered intraperitoneally on day 0 and day 19, and 3 cycles of 1.0 to 2.0% dextran sodium sulfate (DSS) (Thermo Fisher Scientific, J.14489.22…”
InfluentialRole of Gut Microbiome in Immune Regulation and Immune Checkpoint Therapy of Colorectal Cancer
Shi, L., Xu, Y., & Feng, M. (2022) · Digestive Diseases and Sciences · doi:10.1007/s10620-022-07689-0 · Cited by 9
Ginkgo biloba Extract Preventively Intervenes in Citrobacter Rodentium-Induced Colitis in Mice
Chen, T., Chen, Y., Li, K., Chen, Z., Zhao, Q., Fan, Y., Liu, Y., Zhang, S., & Hao, Z. (2023) · Nutrients · doi:10.3390/nu15082008 · Cited by 9
“Olsenella has been shown to support the treatment of colon cancer through the microbial metabolite immune pathway [46].”
BackgroundZhang, Y., Han, S., Xiao, X., Zheng, L., Chen, Y., Zhang, Z., Gao, X., Zhou, S., Yu, K., Huang, L., et al. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1146861 · Cited by 9
“Moreover, the gut microbial components were associated with the response to checkpoint blockade therapies (CBT) and prognosis of cancers (10).”
BackgroundPotential role of gut microbes in the efficacy and toxicity of immune checkpoints inhibitors
Ma, J., Wei, Q., Cheng, X. M., Zhang, J., Zhang, Z., & Su, J. (2023) · Frontiers in Pharmacology · doi:10.3389/fphar.2023.1170591 · Cited by 9
“Similarly, in an experiment with mice, mice that transplanted fecal microbiome from patients who had responded to anti-PD1 treatment were more active to immunotherapy and had a higher density of CD8+T cells after receiving treatment while those receiving stool from non-responsive patients developed resistance Frontier…”
BackgroundInfluentialThe aging tumor metabolic microenvironment
Pilley, S. E., Esparza, E., & Mullen, P. J. (2023) · Current Opinion in Biotechnology · doi:10.1016/j.copbio.2023.102995 · Cited by 10
Lewis, I. A. (2023) · Current Opinion in Biotechnology · doi:10.1016/j.copbio.2023.103027 · Cited by 9
Self-citationThe Microbiome and Pediatric Transplantation
Elgarten, C. W., Margolis, E. B., & Kelly, M. S. (2024) · Journal of the Pediatric Infectious Diseases Society · doi:10.1093/jpids/piad062 · Cited by 10
Functional modification of gut bacteria for disease diagnosis and treatment
Zheng, B., Li, M., Zhang, T., Li, B., Li, Q., Saiding, Q., Chen, W., Guo, M., Koo, S., Ji, X., et al. (2024) · Med · doi:10.1016/j.medj.2024.06.003 · Cited by 9
The influence of microbiota on the efficacy and toxicity of immunotherapy in cancer treatment
Mahmoudian, F., Gheshlagh, S. R., Hemati, M., Farhadi, S., & Eslami, M. (2024) · Molecular Biology Reports · doi:10.1007/s11033-024-10188-2 · Cited by 15
“However, butyrate also promotes T-reg cell differen - tiation in the colon and liver, which may reduce immuno-therapy efficacy [ 17, 18].”
Cutting‐Edge Advancements in the Antibiotics‐Gut Microbiota‐Urinary Tumour Axis
Wang, J., Li, D., Wu, R., & Feng, D. (2025) · Cell Proliferation · doi:10.1111/cpr.70023 · Cited by 9
Pathological environment directed in situ peptidic supramolecular assemblies for nanomedicines
Chen, J., Zhao, Y., Yao, Q., & Gao, Y. (2021) · Biomedical Materials · doi:10.1088/1748-605x/abc2e9 · Cited by 9
Wong, M., Barbulescu, P., Coburn, B. A., & Reguera-Nuñez, E. (2021) · Microbes and Infection · doi:10.1016/j.micinf.2021.104804 · Cited by 9
Role of Bacteria in the Development of Colorectal Cancer
Thomas, R. M. (2023) · Clinics in Colon and Rectal Surgery · doi:10.1055/s-0042-1760679 · Cited by 9
Mining the Gut Microbiota for Microbial-Based Therapeutic Strategies in Cancer Immunotherapy
Li, B., Gong, T., Hao, Y., Zhou, X., & Cheng, L. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.721249 · Cited by 9
“Especially, Bifidobacterium species have been demonstrated to enhance the response to ICIs in animal models by several studies (28, 34, 41).”
BackgroundInfluentialHarnessing Microbiota to Improve Immunotherapy for Gastrointestinal Cancers
Goc, J., & Sonnenberg, G. F. (2022) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-22-0164 · Cited by 8
Qin, B., Li, Z., Zhu, Q., Chen, T., Lan, W., Cui, Y., Azad, M. A. K., & Kong, X. (2024) · Animals · doi:10.3390/ani14192786 · Cited by 11
“Olsenella has been shown to have better antitumor immune effects and anti-CTLA-4 efficacy than Colidextribacter species in a murine tumor model [40].”
BackgroundRaudenská, M., Bugajová, M., Kalfeřt, D., Plzák, J., Šubrt, A., Tesařová, P., & Masařík, M. (2024) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2024.189216 · Cited by 9
Unraveling the Role of the Microbiota in Cancer Immunotherapy: A New Frontier
Wang, S., Li, S., Zhang, M., Liu, R., Ye, X., Mao, S., Yu, J., Xie, X., & Tan, W. (2025) · Research · doi:10.34133/research.0744 · Cited by 13
From dysbiosis to precision therapy: decoding the gut-bladder axis in bladder carcinogenesis
Liu, Z.-Q., Yang, X., Chen, J., Ge, S.-C., Dai, S., Zhu, S., & Xian, Z. (2025) · Frontiers in Oncology · doi:10.3389/fonc.2025.1630726 · Cited by 11
Microbial Metabolic Pathways Guide Response to Immune Checkpoint Blockade Therapy
Mimpen, I. L., Battaglia, T., Parra-Martinez, M., Toner-Bartelds, C., Zeverijn, L. J., Geurts, B. S., Verkerk, K., Hoes, L. R., van Renterghem, A. W. J., Noë, M., et al. (2025) · Cancer Discovery · doi:10.1158/2159-8290.cd-24-1669 · Cited by 11
Gugescu, L., Yang, Y., Kool, J. F., Fyhrquist, N., Wincent, E., & Alenius, H. T. (2025) · Environment International · doi:10.1016/j.envint.2025.109828 · Cited by 8
“Inosine is a degradation product of adenosine and is known to be produced or modulated by gut bacteria (Mager et al., 2020).”
Advanced oral therapies for colorectal cancer via nanomedicine and microbiota modulation
Wang, Y., Chen, C., Xiao, X. H., Kang, Y., He, J., Beloqui, A., & Xu, Y. (2025) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2025.115741 · Cited by 10
Xiong, C., Chen, Z., Wu, X., Zhang, C., Yuan, Z., Wang, X., Xiao, Z., Chen, Y., Deng, S., Wu, X., et al. (2025) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2025.178401 · Cited by 10
Rewiring T Cell Metabolism to Enhance CAR T Cell Function in Solid Tumor Microenvironments
Song, A. W., & Song, X. (2025) · Pharmaceutics · doi:10.3390/pharmaceutics17121520 · Cited by 9
“Through adenosine deaminase (ADA)-mediated conversion, extracellular adenosine can be degraded into inosine (Ino), a metabolite that is not immunosuppressive but rather can serve as an alternative fuel source for T cells [54,55].”
Tumor Immunotherapy and Microbiome: From Bench‐to‐Bedside Applications
Lin, A., Xiong, M., Jiang, A., Chen, L., Huang, L., Li, K., Wong, H. Z. H., Zhang, J., Liu, Z., Cheng, Q., et al. (2026) · MedComm · doi:10.1002/mco2.70454 · Cited by 11
“In patients receiving ICI therapy, microbial metabolites (specifically inosine) effectively activate intestinal T cells, thereby enhancing immunotherapy efficacy [219].”
Zhou, H., Sun, R., Nie, X., Xia, L., Dong, H., Liu, Y., Hou, S., Dong, W., Zhu, X., Yao, Y., et al. (2026) · Nature Microbiology · doi:10.1038/s41564-026-02279-6 · Cited by 14
“Indeed, several commensal bacteria have been shown to be capable of promoting T cell responses by modulating the activation and maturation of DCs 8,13,45 .”
Microbiota-derived metabolites as modulators of cancer immunotherapy response
Toner-Bartelds, C., Mimpen, I. L., Parra-Martinez, M., Burgering, B. M. T., & Voest, E. E. (2026) · Nature Communications · doi:10.1038/s41467-026-72178-1 · Cited by 10
“This activation subsequently results in the production of Th1-stimulating factors, including IL-12 receptor and IFN-γ , thereby boosting ICB response 55 .”
The gut wall's potential as a partner for precision oncology in immune checkpoint treatment.
Lopez, S. H., Jalving, M., Fehrmann, R., Nagengast, W., de Vries, E. D., & de Haan, J. D. (2022) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2022.102406 · Cited by 8
Vilbert, M., Koch, E. C., Rose, A. A. N., Laister, R. C., Gray, D., Sotov, V., Penny, S. L., Spreafico, A., Hogg, D., Pinto, D. M., et al. (2023) · Cancers · doi:10.3390/cancers15143708 · Cited by 10
CSF-1R+ Macrophages Control the Gut Microbiome–Enhanced Liver Invariant NKT Function through IL-18
Ma, C., McCallen, J., McVey, J. C., Trehan, R., Bauer, K. C., Zhang, Q., Ruf, B., Wang, S., Lai, C. W., Trinchieri, G., et al. (2023) · The Journal of Immunology · doi:10.4049/jimmunol.2200854 · Cited by 9
Bacterial Flagellum–Drug Nanoconjugates for Carrier‐Free Immunochemotherapy
Fu, Z., Wang, L., Guo, H., Lin, S., Huang, W., & Pang, Y. (2023) · Small · doi:10.1002/smll.202306303 · Cited by 11
Arğa, K. Y., Attia, H., & Aziz, R. K. (2024) · OMICS A Journal of Integrative Biology · doi:10.1089/omi.2023.0254 · Cited by 8
“The microbiome influences the immune response, drug metabolism, and even the development of chemotherapy-induced toxicities, and has been associated with cancer risk and treatment outcomes (Chrysostomou et al., 2023; Mager et al., 2020).”
Wu, G., Liao, J., Zhu, X., Zhang, Y., Lin, Y., Zeng, Y., Zhao, J., Zhang, J., Yao, T., Shen, X., et al. (2024) · Phytomedicine · doi:10.1016/j.phymed.2024.155727 · Cited by 9
Immunotherapy efficacy and toxicity: Reviewing the evidence behind patient implementable strategies
Verhaert, M., & Aspeslagh, S. (2024) · European Journal of Cancer · doi:10.1016/j.ejca.2024.114235 · Cited by 11
Study of Microbiota Associated to Early Tumors Can Shed Light on Colon Carcinogenesis
Aspesi, A., Vecchia, M. L., Sala, G., Ghelardi, E., & Dianzani, I. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms252413308 · Cited by 8
Beyond Tumor Borders: Intratumoral Microbiome Effects on Tumor Behavior and Therapeutic Responses
Harmak, Z., Kone, A.-S., Ghouzlani, A., Ghazi, B., & Badou, A. (2024) · Immune Network · doi:10.4110/in.2024.24.e40 · Cited by 8
Saadh, M. J., Allela, O. Q. B., Kareem, R. A., Sanghvi, G. V., Ballal, S., Naidu, K. S., Bareja, L., Chahar, M., Gupta, S., Sameer, H. N., et al. (2025) · Gene · doi:10.1016/j.gene.2025.149380 · Cited by 9
Metadata
- Authors
- Mager, L. F., Burkhard, R., Pett, N., Cooke, N. C. A., Brown, K., Ramay, H., Paik, S., Stagg, J., Groves, R. A., Gallo, M., Lewis, I. A., Geuking, M. B., & McCoy, K. D.
- Affiliations
- University of Calgary (CA)
- Centre Hospitalier de l’Université de Montréal (CA)
- Corresponding author
- Mager, Lukas F.
- McCoy, Kathy D.
- ORCID
- Venue
- Science
- Published
- 2020-09-18
- Volume
- 369
- Issue
- 6510
- Pages
- 1481-1489
- ISSN
- 0036-8075 (ISSN-L)
- 1095-9203
- OpenAlex
- W3049052172
- Semantic Scholar
- 041ece73120d89c36e2870fa3f1b95b4ebdafab2
- Cited by
- 1,407
- References
- 65
- Citations by year
- 2026: 240 · 2025: 280 · 2024: 260 · 2023: 247 · 2022: 220 · 2021: 134 · 2020: 25
- FWCI
- 56.87
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Science (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Canadian Institutes of Health Research (PJT-165930, PJT-156073)
- Natural Sciences and Engineering Research Council of Canada
- Swiss National Science Foundation
- Alberta Innovates
- Topics
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Gut microbiota and health
- Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
- Keywords
- inosine, gut microbiota, immune checkpoint inhibitors, cancer immunotherapy, antitumor immunity, microbial metabolites, T cell activation, colorectal cancer, bladder cancer, melanoma, immunotherapy response
- MeSH terms
- Gastrointestinal Microbiome, Lactobacillus johnsonii, Animals, Antibodies, Bifidobacterium, Urinary Bladder Neoplasms, Female, Immunotherapy, Inosine, Intestinal Neoplasms, Male, Melanoma, Mice, Inbred C57BL, Neoplasms, Experimental, Skin Neoplasms, T-Lymphocytes, Receptor, Adenosine A2A, Mice, B7-H1 Antigen, CTLA-4 Antigen
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.